MOBI-C CERVICAL DISC PROSTHESIS (ONE-LEVEL INDICATION)
Highridge Medical, LLC · Decision date Aug 7, 2013
What did the FDA approve?
The FDA approved the MOBI-C Cervical Disc Prosthesis for one-level use in skeletally mature patients requiring reconstruction of the disc from C3-C7 after single-level discectomy. The stated indication covers intractable radiculopathy with or without neck pain, or myelopathy, tied to a single-level abnormality confirmed by CT, MRI, or X-ray showing herniated nucleus pulposus, spondylosis with osteophytes, or visible loss of disc height compared to adjacent levels.
The device is implanted using an anterior approach. The approval statement says patients should have failed at least six weeks of conservative treatment or shown progressive signs or symptoms despite nonoperative treatment before implantation. This decision does not establish independent proof of safety or clinical effectiveness beyond the FDA's approval action for the specified one-level indication.
FDA approval order statement
APPROVAL FOR THE MOBI-C CERVICAL DISC PROSTHESIS. THIS DEVICE IS INDICATED IN SKELETALLY MATURE PATIENTS FOR RECONSTRUCTION OF THE DISC AT ONE LEVEL FROM C3-C7 FOLLOWING SINGLE-LEVEL DISCECTOMY FOR INTRACTABLERADICULOPATHY (ARM PAIN AND/OR A NEUROLOGICAL DEFICIT) WITH OR WITHOUT NECK PAIN OR MYELOPATHY DUE TO A SINGLE-LEVEL ABNORMALITY LOCALIZED TO THE LEVEL OF THE DISC SPACE AND AT LEAST ONE OF THE FOLLOWING CONDITIONS CONFIRMED BY RADIOGRAPHIC IMAGING (CT, MRI, X-RAYS): HERNIATED NUCLEUS PULPOSUS, SPONDYLOSIS (DEFINED BY THE PRESENCE OF OSTEOPHYTES), AND/OR VISIBLE LOSS OF DISC HEIGHT COMPARED TO ADJACENT LEVELS. THE MOBI-C CERVICAL DISC PROSTHESIS IS IMPLANTED USING AN ANTERIOR APPROACH. PATIENTS SHOULD HAVE FAILED AT LEAST 6 WEEKS OF CONSERVATIVE TREATMENT ORDEMONSTRATED PROGRESSIVE SIGNS OR SYMPTOMS DESPITE NONOPERATIVE TREATMENT PRIOR TO IMPLANTATION OF THE MOBI-C CERVICAL DISC PROSTHESIS.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Orthopedic
- Decision date
- Aug 7, 2013
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P110002
- Regulatory pathway
- Premarket approval application
- Applicant
- Highridge Medical, LLC
- Product code
- MJO
- Decision code
- APPR
- Decision date
- Aug 7, 2013
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, intervertebral disc.
- Applicant
- Highridge Medical, LLC
- Product code
- MJO
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P110002 received
Application receipt date recorded by FDA.
P110002 · FDA decision
APPR
P110002/S040 · Related supplement
Mobi-C Cervical Disc Prosthesis for use at One Level
Timeline entries are records held by MedtechLedger for P110002. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P110002
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Highridge Medical, LLC | PMA supplement | Sep 16, 2026 | FDA |
Explore the linked device profile
Other records with product code MJO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
BAGUERAC Cervical Disc ProsthesisP250042/S002 | Spineart USA, Inc. | PMA supplement | Sep 22, 2026 | FDA |
Synergy DiscP250028/S003 | Synergy Spine Solutions, Inc. | PMA supplement | Sep 17, 2026 | FDA |
| Highridge Medical, LLC | PMA supplement | Sep 16, 2026 | FDA | |
prodisc C NovaP070001/S031 | Centinel Spine, LLC | PMA supplement | Sep 9, 2026 | FDA |
| Spineart USA, Inc. | PMA approval | Aug 10, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Highridge Medical, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 10225 Westmoor Dr., Westminister, CO, 80021
Sources and methodology
- Original FDA record: P110002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



